Datopotamab deruxtecan is an anti‑TROP2 antibody–drug conjugate that binds TROP2 on tumor cells, is internalized, and releases the membrane‑permeable topoisomerase I inhibitor payload deruxtecan via a cleavable linker in lysosomes. The released payload inhibits Topo I, causing DNA damage and tumor cell death, with potential bystander killing of adjacent cells.